Results 11 to 20 of about 1,454 (181)
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review
Brain Sciences, 2022 Calcitonin gene-related peptide (CGRP) antagonists are a class of medications that act as antagonists of the CGRP receptor or ligand. They can be divided into monoclonal antibodies and non-peptide small molecules, also known as gepants.
Jamir Pitton Rissardo +1 more
doaj +4 more sources
The pharmacotherapeutic management of episodic and chronic migraine with gepants [PDF]
Expert Opinion on Pharmacotherapy, 2023 The small molecule non-peptide calcitonin gene-related peptide (CGRP) receptor antagonists named gepants offer a breakthrough novel approach in migraine acute and prophylactic drug treatment. This review aimed to determine the place of gepants in the treatment of episodic and chronic migraine.The new generation gepants are ubrogepant, atogepant ...
Tajti János +3 more
openaire +5 more sources
Progress in treating migraines: promising prospects for a better tomorrow
Bulletin of the National Research Centre, 2023 Background Migraine is a debilitating disorder that undoubtedly has a significant impact both clinically and socially. New treatment options are necessary in Iran due to issues with tolerance, interactions, contraindications, and the lack of ...
Seyed-Amirabbas Ahadiat +1 more
doaj +2 more sources
Calcitonin gene-related peptide (CGRP) was suggested to play an important role in primary headaches as far back as 1985 and has been confirmed as playing a significant role in migraine pathophysiology. CGRP receptor antagonists are becoming more and more
Pablo Irimia +2 more
core +4 more sources
Gepants for the treatment of migraine
Expert Opinion on Investigational Drugs, 2019 Migraine is the most common of all neurological disorders. A breakthrough in migraine treatment emerged in the early nineties with the introduction of 5-HT1B/D receptor agonists called triptans. Triptans are used as the standard of care for acute migraine; however, they have significant limitations such as incomplete and inconsistent pain relief, high ...
Negro A., Martelletti P.
openaire +3 more sources
A non‐oral gepant for acute treatment of migraine [PDF]
Headache: The Journal of Head and Face Pain, 2022 Migraine is the leading cause of years lived with disability in people under 50 and its burden is increased by calcitonin gene-related peptide (CGRP)-driven chronicity. Newly approved small molecules that antagonize the CGRP receptor, gepants, have advanced from the hepatotoxic first-generation telcagepant to third-generation intranasal zavegepant ...
Damiana Scuteri +4 more
core +5 more sources
eNeurologicalSci, 2022 Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high burden of migraine in terms of disability, there has been an effort to develop migraine specific therapies that has led to the ...
Oyindamola I. Ogunlaja, Peter J. Goadsby
doaj +2 more sources
The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse [PDF]
The Journal of Headache and Pain, 2019 Background The treatment of migraine is impeded by several difficulties, among which insufficient headache relief, side effects, and risk for developing medication overuse headache (MOH).
Willem Sebastiaan van Hoogstraten +1 more
doaj +2 more sources
The impact of headache specialist density and the introduction of gepants and lasmitidan on prescriptions for acute migraine treatments: a regression and interrupted time series analysis [PDF]
Frontiers in NeurologyBackgroundUnderstanding all factors that affect a patient’s acute migraine treatment care is crucial. We sought to determine the impact of headache specialist density and the introduction of the gepants and lasmiditan on the prescription of acute ...
Leon S. Moskatel +2 more
doaj +2 more sources
The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis [PDF]
The Journal of Headache and Pain, 2023 Objective While there are several trials that support the efficacy of various drugs for migraine prophylaxis against placebo, there is limited evidence addressing the comparative safety and efficacy of these drugs.
Christian Lampl +10 more
doaj +2 more sources